drugset / Trial / NCT00246584

A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)

NCT00246584

Phase 2 Completed 300 enrolled Novartis
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)

Timeline

Start
2004-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule

Indications